SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Discontinues Nemtabrutinib Clinical Development Program

Merck discontinued the clinical development program evaluating nemtabrutinib (MK-1026), an investigational BTK inhibitor.

MRK

Related stories